Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitsuhiro Matsuda

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Cancer Immunology, Immunotherapy : CII|May 17, 2024
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patientsYutaka Shimazu, Junya Kanda, Yoshiyuki Onda, et al.
International Journal of Hematology|May 4, 2022
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trialYasushi Miyazaki, Toru Kiguchi, Shinya Sato, et al.
European Journal of Haematology|January 21, 2021
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysisTeruhito Takakuwa, Ryosuke Yamamura, Kensuke Ohta, et al.
International Journal of Hematology|January 31, 2018
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma ForumYayoi Matsumura-Kimoto, Junya Kuroda, Hitomi Kaneko, et al.
Therapeutic Advances in Hematology|July 5, 2022
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysisYoshiyuki Onda, Junya Kanda, Hitomi Kaneko, et al.
International Journal of Hematology|November 28, 2023
Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)Kensuke Usuki, Shigeki Ohtake, Sumihisa Honda, et al.
International Journal of Hematology|September 5, 2023
Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma ForumYuji Shimura, Hirohiko Shibayama, Aya Nakaya, et al.
International Journal of Hematology|December 13, 2023
Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)Kensuke Usuki, Shigeki Ohtake, Sumihisa Honda, et al.
Scientific Reports|March 29, 2023
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulinYutaka Shimazu, Junya Kanda, Satoru Kosugi, et al.
Blood Advances|September 13, 2021
Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemiaIsamu Sugiura, Noriko Doki, Tomoko Hata, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Cancer Immunology, Immunotherapy : CII|May 17, 2024
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patientsYutaka Shimazu, Junya Kanda, Yoshiyuki Onda, et al.
International Journal of Hematology|May 4, 2022
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trialYasushi Miyazaki, Toru Kiguchi, Shinya Sato, et al.
European Journal of Haematology|January 21, 2021
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysisTeruhito Takakuwa, Ryosuke Yamamura, Kensuke Ohta, et al.
International Journal of Hematology|January 31, 2018
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma ForumYayoi Matsumura-Kimoto, Junya Kuroda, Hitomi Kaneko, et al.
Therapeutic Advances in Hematology|July 5, 2022
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysisYoshiyuki Onda, Junya Kanda, Hitomi Kaneko, et al.
International Journal of Hematology|November 28, 2023
Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)Kensuke Usuki, Shigeki Ohtake, Sumihisa Honda, et al.
International Journal of Hematology|September 5, 2023
Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma ForumYuji Shimura, Hirohiko Shibayama, Aya Nakaya, et al.
International Journal of Hematology|December 13, 2023
Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)Kensuke Usuki, Shigeki Ohtake, Sumihisa Honda, et al.
Scientific Reports|March 29, 2023
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulinYutaka Shimazu, Junya Kanda, Satoru Kosugi, et al.
Blood Advances|September 13, 2021
Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemiaIsamu Sugiura, Noriko Doki, Tomoko Hata, et al.
Pageof 10